The promise of blood-based Alzheimer's detection could be complicated by biological sex differences that affect how accurately these tests identify early disease. This finding challenges the one-size-fits-all approach currently dominating biomarker development and suggests clinicians may need to interpret results differently for men versus women.
Analyzing plasma samples from the Alzheimer's Disease Neuroimaging Initiative, researchers discovered distinct patterns in key biomarkers between sexes. Cognitively normal men showed lower amyloid beta-42 and glial fibrillary acidic protein levels, but higher phosphorylated tau-217 ratios. Among those already experiencing cognitive decline, women exhibited elevated inflammatory markers and tau proteins. Most significantly, the predictive accuracy varied dramatically by sex: p-tau217 markers demonstrated superior specificity in identifying amyloid pathology among healthy women, while showing better sensitivity in cognitively impaired men.
These sex-specific patterns extend beyond diagnostic accuracy to prognostic capability. The phosphorylated tau markers predicted cognitive decline in healthy women but failed to show the same predictive power in men, suggesting fundamental differences in how Alzheimer's pathology manifests and progresses between sexes. This discovery arrives as blood-based biomarkers near clinical implementation, with multiple tests approaching FDA approval. The research indicates that while separate cutoff values for men and women may not be necessary, ignoring sex differences could compromise diagnostic precision and treatment timing. For a disease where women face disproportionately higher risk, these findings underscore the critical need for sex-stratified validation studies before widespread clinical deployment.